Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zelira TherapeuticsASX:ZLD 3-Year Share Buyback Ratio is -7.50 as of Jun. 2025. The stock has 7 warning signs investors should review. Among 1,187 Biotechnology companies, Zelira Therapeutics ranks better than 58.8% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Zelira Therapeutics's current 3-Year Share Buyback Ratio was -7.50%.
The historical rank and industry rank for Zelira Therapeutics's 3-Year Share Buyback Ratio or its related term are showing as below:
ASX:ZLD'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -451.8 Med: -27.1 Max: -0.1
Current: -7.5
During the past 13 years, Zelira Therapeutics's highest 3-Year Share Buyback Ratio was -0.10%. The lowest was -451.80%. And the median was -27.10%.
ASX:ZLD's 3-Year Share Buyback Ratio is ranked better than 58.8% of 1187
companies
in the Biotechnology industry
Industry Median: -11.8
vs ASX:ZLD: -7.50
Zelira Therapeutics (ASX:ZLD) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Zelira Therapeutics 3-Year Share Buyback Ratio Related Terms
ASX:ZLD vs GNPX, SXTP, GLMD: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Zelira Therapeutics's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zelira Therapeutics 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zelira Therapeutics's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Zelira Therapeutics's 3-Year Share Buyback Ratio falls into.
Zelira Therapeutics 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -7.50 mean?
Zelira Therapeutics (ASX:ZLD) has a 3-Year Share Buyback Ratio of -7.50 as of Jun. 2025. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Zelira Therapeutics and its competitors. According to the industry distribution chart, Zelira Therapeutics ranks #489 out of 1187 companies in the Biotechnology industry, placing it in the top 41.2%.
Is Zelira Therapeutics' 3-Year Share Buyback Ratio too high?
Zelira Therapeutics' current 3-Year Share Buyback Ratio is -7.50. Based on the distribution chart, Zelira Therapeutics ranks #489 out of 1187 companies in the Biotechnology industry, which is above the industry midpoint.
How does Zelira Therapeutics' 3-Year Share Buyback Ratio compare to GNPX and SXTP?
According to the Biotechnology industry distribution chart, Zelira Therapeutics ranks #489 out of 1187 companies for 3-Year Share Buyback Ratio. This puts Zelira Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Zelira Therapeutics and its competitors. Zelira Therapeutics's current 3-Year Share Buyback Ratio is -7.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Zelira Therapeutics (ASX:ZLD) has a current 3-Year Share Buyback Ratio of -7.50. The stock's GF Value™ is A$0.12, compared to a current price of A$0.50 — trading 316.7% above its estimated fair value. The current 3-Year Share Buyback Ratio is -7.50. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Zelira Therapeutics (ASX:ZLD), the current 3-Year Share Buyback Ratio is -7.50 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ZLD has been successfully added to your 
